JAK2


Also found in: Acronyms.

JAK2

A gene on chromosome 9p24 that encodes a non-receptor protein tyrosine kinase, which is involved in a subset of cytokine receptor signalling pathways, including for cell growth, development, differentiation and histone modifications. JAK2 mediates essential signalling events in both innate and adaptive immunity, and is required for responses to gamma interferon. It plays a key role in signal transduction by associating with type-I receptors (e.g., growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO)) or type-II receptors (e.g., IFN-alpha, IFN-beta, IFN-gamma and a wide range of interleukins).
References in periodicals archive ?
JAK2 V617F-positive ET was confirmed after bone marrow biopsy and gene testing.
This clearance for the company's ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) was awarded by the US Food and Drug Administration (FDA).
3 A meta-analysis showed that the mean prevalence of MPD and JAK2 mutation was 31.
Leptin, LEPR, JAK2, STAT3, KISS1, TRPC5) were analyzed through quantitative real-time PCR (qRT-PCR) and using the cDNA of various tissues in different stages of puberty as templates.
Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: A case report.
The JAK2 and CALR mutations were thought to be mutually exclusive, but the homozygous sample was double-positive for both JAK2 and CALR.
The final cell suspensions were divided into four major groups: Control group, HMGB1 group (HMGB1 was added to pancreatic acinar cells at a final concentration of 1 [micro]g/mL), AG490 group (the JAK2 inhibitor AG490 was added to the cultured cells 30 minutes before HMGB1 induction at a final concentration of 25 pmol/L), and the rapamycin group (the STAT3 inhibitor rapamycin was added at a final concentration of 40 ng/ml 30 minutes before the HMGB1 induction).
After GH binds to GHR, special conformation change(s) within the pre-dimerized GHR occur, JAK2 is then activated, and downstream signaling molecules (such as STAT5, STAT3, STAT1, ERK1/2, and AKT) are triggered (Brooks et al.
There are rare cases of eosinophilic myeloproliferative neoplasms associated with JAK2 V617F.
and ET are Philadelphia (ph) negative MPD's in which JAK2 V617F mutation (2,3) is responsible for clonal proliferation of blood cells.
Baricitinib has roughly equal affinity for JAK1 and JAK2, preventing the intracellular signaling cascades that lead to the production of IL-6 and IL-23, thereby reducing inflammation.